A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: Effect on Tau and amyloid pathologies in vitro

Journal of Neurochemistry

Volumn 133, Issue 3, 2015, Pages 440-451

  Coutadeur, Séverine ^a   Benyamine, Hélène ^a   Delalonde, Laurence ^a   De Oliveira, Catherine ^a   Leblond, Bertrand ^a   Foucourt, Alicia ^b   Besson, Thierry ^b   Casagrande, Anne Sophie ^a   Taverne, Thierry ^a   Girard, Angélique ^a   Pando, Matthew P ^a   Désiré, Laurent ^a  

^a Diaxonhit   (France)

^b UNIVERSITÉ ET INSA DE ROUEN   (France)

Author keywords

Alzheimer's disease; amyloid precursor, protein; DYRK1A; EHT 5372; kinase; Tau

Indexed keywords

AMYLOID BETA PROTEIN; METHYL 9 (2,4 DICHLOROPHENYLAMINO) THIAZOLO[5,4 F]QUINAZOLINE 2 CARBIMIDATE; PHOSPHOTRANSFERASE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; DYRK KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EMBRYO; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; HEK293 CELL LINE; HUMAN; METABOLISM; TREATMENT OUTCOME; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; HEK293 CELLS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR; TAU PROTEINS; TREATMENT OUTCOME;

EID: 84927129691     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13018     Document Type: Article

References (46)

1. Augustinack J. C., Schneider A., Mandelkow E. M., and, Hyman B. T., (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103, 26-35.
2. Azorsa D. O., Robeson R. H., Frost D., et al,. (2010) High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. BMC Genom. 12, 11-25.
3. Ballatore C., Lee V. M., and, Trojanowski J. Q., (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672.
4. Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F. J., and, Joost H. G., (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem. 273, 25893-25902.
5. Becker W., Soppa U., and, Tejedor F. J., (2014) DYRK1A: a potential drug target for multiple down syndrome neuropathologies. CNS Neurol. Disord. Drug Targets. 13, 26-33.
6. Braak H., and, Braak E., (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
7. Brouillette J., Caillierez R., Zommer N., Alves-Pires C., Benilova I., Blum D., De Strooper B., and, Buée L., (2012) Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. J. Neurosci. 32, 7852-7861.
8. De la Torre R., De Sola S., Pons M., et al,. (2014) Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol. Nutr. Food Res. 58, 278-288.
9. Debdab M., Carreaux F., Renault S., et al,. (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. Modulation of alternative pre-RNA splicing. J. Med. Chem. 54, 4172-4186.
10. Ferrer I., Barrachina M., Puig B., Martínez de Lagrán M., Martí E., Avila J., and, Dierssen M., (2005) Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol. Dis. 20, 392-400.
11. Friedman E., (2007) Mirk/Dyrk1B in cancer. J. Cell. Biochem. 102, 274-279.
12. Frost D., Meechoovet B., Wang T., Gately S., Giorgetti M., Shcherbakova I., and, Dunckley T., (2011) β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS ONE 6, e19264.
13. Göckler N., Jofre G., Papadopoulos C., Soppa U., Tejedor F. J., and, Becker W., (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J. 276, 6324-6337.
14. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., and, Binder L.I., (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913-4917.
15. Guedj F., Sébrié C., Rivals I., et al,. (2009) Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 4, e4606.
16. Ittner L. M., Ke Y. D., Delerue F., et al,. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
17. Kimura R., Kamino K., Yamamoto M., et al,. (2007) The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum. Mol. Genet. 16, 15-23.
18. LaPointe N. E., Morfin G., Pigino G., Gaisina I. N., Kozikowski A. P., Binder L. I., and, Brady S. T., (2009) The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 87, 440-451.
19. Leblond B., Casagrande A.-S., Desire L., Foucourt A., and, Besson T., Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. Patent Application Number: WO 2013 /026806A1. Publication date: February 28, 2013. Priority date: August 17, 2012.
20. Leder S., Weber Y., Altafaj X., Estivill X., Joost H. G., and, Becker W., (1999) Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. Biochem. Biophys. Res. Commun. 254, 474-479.
21. Li Y., Sattler R., Yang E. J., Nunes A., Ayukawa Y., Akhtar S., Ji G., Zhang P. W., and, Rothstein J. D., (2011) Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacol. 60, 1168-1175.
22. Lindwall G., and, Cole R. D., (1999) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301-5305.
23. Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., and, Duff K., (2012) Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302.
24. Marcade M., Bourdin J., Loiseau N., Peillon H., Rayer A., Drouin D., Schweighoffer F., and, Désiré L., (2008) Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 106, 392-404.
25. Martin L., Latypova X., Wilson C. M., Magnaudeix A., Perrin M. L., Yardin C., and, Terro F., (2013) Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12, 289-309.
26. Medda F., Smith B., Gokhale V., Shaw A., Dunckley T., and, Hulme C., (2013) Beyond Secretases: kinase inhibitors for the treatment of Alzheimer's Disease. Annu. Rev. Med. Chem. 48, 57-71.
27. Michel C. H., Kumar S., Pinotsi D., Tunnacliffe A., St George-Hyslop P., Mandelkow E., Mandelkow E. M., Kaminski C. F., and, Kaminski Schierle G. S., (2014) Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J. Biol. Chem. 289, 956-967.
28. Park J., Song W. J., and, Chung K. C., (2009) Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci. 66, 3235-3240.
29. Patra S. K., Rizzi F., Silva A., Rugina D. O., and, Bettuzzi S., (2008) Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts. J. Physiol. Pharmacol. 59, 217-235.
30. Qian W., Liang H., Shi J., Jin N., Grundke-Iqbal I., Iqbal K., Gong C. X., and, Liu F., (2011) Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res. 39, 6161-6171.
31. Rapoport M., Dawson H. N., Binder L. I., Vitek M. P., and, Ferreira A., (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99, 6364-6369.
32. Roberson E. D., Scearce-Levie K., Palop J. J., Yan F., Cheng I. H., Wu T., Gerstein H., Yu G. Q., and, Mucke L., (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
33. Ryoo S. R., Jeong H. K., Radnaabazar C., et al,. (2007) DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 282, 34850-34857.
34. Ryoo S. R., Cho H. J., Lee H. W., et al,. (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J. Neurochem. 104, 1333-1344.
35. Schraen-Maschke S., Sergeant N., Dhaenens C. M., et al,. (2008) Tau as a biomarker of neurodegenerative diseases. Biomark. Med. 2, 363-384.
36. Sergeant N., Bretteville A., Hamdane M., et al,. (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 5, 207-224.
37. Shi J., Zhang T., Zhou C., et al,. (2008) Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J. Biol. Chem. 283, 28660-28669.
38. Smith B., Medda F., Gokhale V., Dunckley T., and, Hulme C., (2012) Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem. Neurosci. 3, 857-872.
39. Tahtouh T., Elkins J. M., Filippakopoulos P., et al,. (2012a) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 55, 9312-9330.
40. Tahtouh T., Fedorov O., Lozach O., Carreaux F., Bazureau J. P., Meunier J., Maurice T., Knapp S., and, Meijer L., (2012b) Leucettines, a family of pharmacological inhibitors of DYRKs & CLKs kinases derived from the marine sponge Leucettamine B. Planta Med. 78, PD1.
41. Vázquez-Higuera J. L., Sánchez-Juan P., Rodríguez-Rodríguez E., et al,. (2009) DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort. BMC Med. Genet. 10, 129.
42. Vingtdeux V., Hamdane M., Gompel M., et al,. (2005) Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol. Dis. 20, 625-637.
43. Wang J. Z., Xia Y. Y., Grundke-Iqbal I., and, Iqbal K., (2013) Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis. S1, S123-S139.
44. Wegiel J., Dowjat K., Kaczmarski W., et al,. (2008) The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol. 116, 391-394.
45. Wegiel J., Gong C. X., and, Hwang Y. W., (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J. 278, 236-245.
46. Woods Y. L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., and, Proud C. G., (2001) The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609-615.